z-logo
Premium
Tubulin‐targeting agent combination therapies: dosing schedule could matter
Author(s) -
Solary Eric
Publication year - 2013
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.12101
Subject(s) - dosing , vincristine , pharmacology , doxorubicin , medicine , antagonist , drug , chemotherapy , cyclophosphamide , receptor
Tubulin-binding agents are potent cytotoxic drugs that are largely used to treat haematological malignancies and solid tumours. In this issue of British Journal of Pharmacology, doxorubicin was shown to decrease the activity of vincristine when administered simultaneously, unless cell cycle arrest mechanisms were disrupted. This observation emphasizes the need to better explore schedule-dependent antagonist effects in anticancer drug combination therapies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here